Michele Marchioni1,2, Joseph G Cheaib3, Toshio Takagi4, Nicola Pavan5, Alessandro Antonelli6, Wourter Everaerts7, Matthias Heck8, Koon H Rha9, Alexandre Mottrie10, Jihad Kaouk11, Umberto Capitanio12, Estevão Lima13, Alessandro Veccia6,14, Simone Crivellaro15, Estefania Linares16, Antonio Celia17, Francesco Porpiglia18, Riccardo Autorino14, Marta DI Nicola1, Luigi Schips2, Phillip M Pierorazio3, Maria Carmen Mir19. 1. Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, G. D'Annunzio University, Chieti, Chieti-Pescara, Italy. 2. Department of Urology, SS Annunziata Hospital, G. D'Annunzio University, Chieti, Chieti-Pescara, Italy. 3. Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD, USA. 4. Department of Urology, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan. 5. Department of Medical, Surgical and Health Science, Clinic of Urology, University of Trieste, Trieste, Italy. 6. Department of Urology, Spedali Civili Hospital, University of Brescia, Brescia, Italy. 7. Department of Urology, KU Leuven, Leuven, Belgium. 8. Department of Urology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany. 9. Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. 10. Department of Urology, Onze Lieve Vrouw Hospital, Aalst, Belgium. 11. Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. 12. Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS San Raffaele Hospital, Milan, Italy. 13. Department of Urology, Hospital of Braga, Braga, Portugal. 14. Division of Urology, VCU Medical Center, Richmond, VA, USA. 15. Department of Urology, University of Illinois, Chicago, IL, USA. 16. Department of Urology, La Paz University Hospital, Madrid, Spain. 17. Department of Urology, San Bassiano Hospital, Bassano del Grappa, Vicenza, Italy. 18. Department of Urology, School of Medicine, San Luigi Gonzaga Hospital, University of Turin, Turin, Italy. 19. Department of Urology, Instituto Valenciano de Oncología (IVO), Valencia, Spain - mirmare@yahoo.es.
Abstract
BACKGROUND: The aim of the study was to test the effect of active surveillance (AS) versus primary intervention (PI) on overall mortality (OM) in elderly patients diagnosed with SRM. METHODS: Elderly patients (75 years or older) diagnosed with SRMs (<4 cm) and treated with either PI (i.e. partial nephrectomy or kidney ablation) or AS between 2009 and 2018 were abstracted from the renal surgery in the elderly (RESURGE) and Delayed Intervention and Surveillance for small Renal Masses (DISSRM) datasets, respectively. OM rates were estimated among groups with Kaplan Meier method and Cox proportional hazards regression models after applying inverse probability of treatment weighting (IPTW). Multivariable logistic regression model was used to estimate IPTW. Covariates of interest were those unbalanced and/or significantly correlated with the treatment choice or with OM. RESULTS: A total of 483 patients were included; 121 (25.1%) underwent AS. Sixty patients (12.4%) died. Overall, 6.7% of all deaths were related to cancer. IPTW-Kaplan Meier curves showed a 5-year overall survival rates of 70.0±3.5% and 73.2±4.8% in AS and PI groups, respectively (IPTW-Log-rank P value=0.308). IPTW-Cox regression model did not show meaningfully increased OM rates in AS group (HR: 1.31, 95% CI: 0.69-2.49). CONCLUSIONS: AS represents an appealing treatment option for very elderly patients presenting with SRM, as it avoids the risks of a PI while not compromising the survival outcomes of these patients.
BACKGROUND: The aim of the study was to test the effect of active surveillance (AS) versus primary intervention (PI) on overall mortality (OM) in elderly patients diagnosed with SRM. METHODS: Elderly patients (75 years or older) diagnosed with SRMs (<4 cm) and treated with either PI (i.e. partial nephrectomy or kidney ablation) or AS between 2009 and 2018 were abstracted from the renal surgery in the elderly (RESURGE) and Delayed Intervention and Surveillance for small Renal Masses (DISSRM) datasets, respectively. OM rates were estimated among groups with Kaplan Meier method and Cox proportional hazards regression models after applying inverse probability of treatment weighting (IPTW). Multivariable logistic regression model was used to estimate IPTW. Covariates of interest were those unbalanced and/or significantly correlated with the treatment choice or with OM. RESULTS: A total of 483 patients were included; 121 (25.1%) underwent AS. Sixty patients (12.4%) died. Overall, 6.7% of all deaths were related to cancer. IPTW-Kaplan Meier curves showed a 5-year overall survival rates of 70.0±3.5% and 73.2±4.8% in AS and PI groups, respectively (IPTW-Log-rank P value=0.308). IPTW-Cox regression model did not show meaningfully increased OM rates in AS group (HR: 1.31, 95% CI: 0.69-2.49). CONCLUSIONS: AS represents an appealing treatment option for very elderly patients presenting with SRM, as it avoids the risks of a PI while not compromising the survival outcomes of these patients.